Plain-English translation of NCT06622005 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new medication called SX-682 combined with three standard multiple myeloma treatments (, daratumumab, and ). SX-682 works by 'unlocking' your immune system so it can better recognize and attack myeloma cancer cells. The study is checking whether this combination is safe and can help people whose myeloma has returned or isn't responding to earlier treatments.
Multiple myeloma often comes back or stops responding to treatments over time, leaving patients with limited options. Researchers hope that by adding this new immune-boosting medication to proven cancer drugs, they can help the immune system fight back more effectively against this stubborn cancer.
You likely qualify if…
You likely don't qualify if…
You would take the new medication by mouth twice daily for 21 days of each 28-day cycle, plus receive the three standard cancer drugs on a set schedule (some as injections, some as IV infusions, some as pills). You would continue this for up to 6 cycles, and if your cancer responds well, you may continue on a maintenance schedule. Throughout the study, you'll have blood tests, bone marrow samples, heart imaging, and scans to monitor your health and how well the treatment is working.
AI-generated summary from trial data · Jul 4, 2026 · Not medical advice
United States